MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BIX02189

CAS No. : 1265916-41-3

MCE 国际站：BIX02189

产品活性：BIX02189 是一种有效的选择性 MEK5 抑制剂，IC₅₀ 为 1.5 nM。BIX02189 也抑制 ERK5 活性，IC₅₀ 为 59 nM。

研究领域：MAPK/ERK Pathway  |  Stem Cell/Wnt

作用靶点：MEK  |  ERK

In Vitro: BIX02189 blocks phosphorylation of ERK5, without affecting phosphorylation of ERK1/2 in sorbitol-stimulated HeLa cells. BIX02189 inhibits ERK5 phosphorylation in a dose dependent manner. Fluvastatin reduces advanced glycation endproduct (AGE)-induced vascular smooth muscle cells (VSMCs) proliferation. To confirm this effect, VSMCs are treated with AGEs in the presence or absence of Fluvastatin and then subject to MTT assay. AGEs are found to dose-dependently induce cell proliferation, and this is significantly suppressed by Fluvastatin. In addition to MTT assay, the similar results are got with cell counting. This suppressive effect of Fluvastatin is prevented when VSMCs are pretreated with BIX02189. Whether ERK5 activation can reduce proliferation is also examined by using Ad-CA-MEK5α encoding a constitutively active mutant form of MEK5α (an upstream kinase of ERK5). AGE-induced proliferation determined by both MTT assay and cell counting is significantly diminished in the presence of Ad-CA-MEK5α, and Nrf2 depletion using siRNA restored AGE-induced proliferation.

In Vivo: Mice are treated with either 10 mg/kg of BIX02189 (in 25% DMSO) or vehicle control (same volume of 25% DMSO) by intraperitoneal injection. The nuclear localization of Nrf2 is inhibited in aortic endothelial cells from mice treated with BIX02189.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Highly Selective Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  Multi-Target Compound Library  |  Trametinib  |  PD98059  |  Mirdametinib  |  Yoda 1  |  U0126-EtOH  |  SCH772984  |  TBHQ  |  Selumetinib  |  Tauroursodeoxycholate  |  Cobimetinib  |  Binimetinib  |  Ulixertinib  |  Honokiol  |  β-Glycerophosphate disodium salt pentahydrate  |  Astragaloside IV  |  Piperlongumine  |  Ravoxertinib  |  Temuterkib  |  C16-PAF  |  Isorhamnetin  |  Avutometinib  |  Lidocaine  |  FR 180204  |  Fucoxanthin  |  Pimasertib  |  RMC-6291

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。